

The synthesis and anti-inflammatory evaluation of 1,2,3-triazole linked isoflavone benzodiazepine hybrids

Gabriel Menghereş,^a Olumayokun Olajide,^b and Karl Hemming^{a*}

^aDepartment of Chemical Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK

^bDepartment of Pharmacy, University of Huddersfield, Huddersfield, HD1 3DH, UK

Email: k.hemming@hud.ac.uk

Dedicated to Professor Jan Bergman on the Occasion of his 80th Birthday

Received mm-dd-yyyy


Accepted mm-dd-yyyy

Published on line mm-dd-yyyy

Dates to be inserted by editorial office

Abstract

Copper catalyzed azide-alkyne cycloaddition was used for the first time to access a small series of eight novel 1,2,3-triazole linked isoflavone benzodiazepine hybrids. As part of this work, a previously unreported alkyne substituted pyrrolo[1,4]benzodiazepine was synthesized using a Sonogashira coupling reaction. Two previously unreported azide substituted isoflavones were also synthesized using TMS-azide as a key reagent. The eight new 1,2,3-triazole linked products, and several precursors, were evaluated as potential anti-inflammatory compounds. This revealed that two of the triazole linked isoflavone benzodiazepine hybrids together with one of the azido-isoflavone precursors showed useful NO inhibitory activity when compared to natural isoflavones.



Keywords: benzodiazepine, triazole, isoflavone, azide, anti-inflammatory, CuAAC

Introduction

Isoflavones such as daidzein **1** and formononetin **2** (see Figure 1) are naturally occurring phytoestrogens that have long been associated with a wide range of biological activities,^{1,2} including anti-inflammatory³ and neuroprotective properties.⁴ This has led to significant interest in the synthesis of this class of compounds and their investigation as potential leads for the development of treatments for neurodegenerative disorders such as Alzheimer's disease (AD).^{4,5,6} The neuroprotective properties of formononetin and their pharmacological origins have been evaluated.⁵ Daidzein has been shown in animal studies to induce improvements in cognitive function by correcting oxidative stress in neuronal cells in the brain,⁶ and its hydroxylated metabolite, 6,7,4'-trihydroxyisoflavone, has been shown to improve learning and memory via activation of the cholinergic system.⁷ It has been clearly established that neuroinflammation is a valid target in AD, and that the microglial cells produced in AD mediate neuroinflammation.^{8,9} The synthetic isoflavone derivative **3**, shown in Figure 1, has been established to be an anti-neuroinflammatory compound with neuroprotective properties, and has shown the ability to improve cognitive ability in an animal model, making it a promising lead compound for the treatment of AD.¹⁰

As part of an ongoing project that is looking at the synthesis and biological evaluation of novel anti-inflammatory and neuroprotective small-ring heterocycles¹¹ and isoflavones,¹² and due to an interest in the chemistry of benzodiazepines,¹³ we have been exploring the synthesis and anti-inflammatory properties of isoflavone benzodiazepine hybrid drugs, and report our results herein. Hybrid drugs seek to covalently link two pharmacophores in one molecule, and aim to produce improved pharmacodynamic and therapeutic profiles.¹⁴ Our choice of a benzodiazepine as the partner to an isoflavone is supported by reports that chronic benzodiazepine users have a lower brain amyloid load where a reduction in neuroinflammation has been identified as the potential pathway.¹⁵ Significantly, there are also reports that the imidazobenzodiazepines **4**,^{16,17} imidazobenzodiazepinones **5**^{18,19} and their pyrrolo-fused analogues **6**²⁰ (Figure 1) offer the potential to aid learning and memory, and may limit the underlying causes of cognitive decline and age associated hyperactivity¹⁹ associated with AD.

We favoured the use of a 1,2,3-triazole as the covalent link between the benzodiazepine and isoflavone moieties because of our familiarity with the use and synthesis of azides,²¹ because of their common use as a linker using very well-known click-chemistry protocols,¹⁴ and also because of the potential that they have to deliver interesting biological activity in their own right. The synthesis and use of hybrid drug candidates containing 1,2,3-triazoles has been recently and extensively reviewed,²² and the synthesis of such compounds also features strongly in a recent review of potential drug candidates for Alzheimer's disease.²³ We are aware that the antimicrobial activity of novel synthetic isoflavone 1,2,3-triazole hybrids has been evaluated,²⁴ that 1,2,3-triazole linked pyrrolobenzodiazepine dimers²⁵ and chalcone hybrids²⁶ have been synthesized and studied as DNA minor groove inhibitors^{25,26} with significant anticancer potential, as have flavone pyrrolobenzodiazepine hybrids joined by an ether link,²⁷ and that hexahydrodibenzodiazepine 1,2,3-triazole hybrids have been reported to be butyrylcholinesterase inhibitors of interest in AD.²⁸ However, we are aware of no reports that have investigated benzodiazepines attached to isoflavones via a 1,2,3-triazole link. In this report, we focus on the synthetic methodology that was used to construct these target molecules. We also report some preliminary biological screening data, the full details of which will be reported elsewhere.





Figure 1. Isoflavones and Benzodiazepines of Interest in AD Research

Results and Discussion

As discussed in the Introduction, we wished to attach isoflavones to benzodiazepines using an azide-alkyne cycloaddition. The previously unreported azides **10** and **11** were obtained as shown in Scheme 1. Thus, resorcinol and 4-nitrophenylacetic acid were reacted together in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ to give a deoxybenzoin intermediate **7** which was formylated and cyclized in the presence of DMF and methanesulfonyl chloride using a modified literature method²⁹ to give the known^{29,30} isoflavone **8**. Reduction to the corresponding previously reported^{29,30} amine **9** was followed by diazotization and azidation with TMS-azide to give the previously unknown azide **10** which was reacted readily with acetic anhydride in pyridine to give the unknown acylated analogue **11**.




Scheme 1. The Synthesis of Azido Isoflavones


As reaction partners for the two isoflavone based azides **10** and **11**, we required the alkyne substituted imidazobenzodiazepines **5** and **6** ($R^2 = C\equiv CH$), the syntheses of which are shown in Scheme 2. The imidazo-fused systems were selected due to the association of these compounds with cognitive enhancement and their potential usefulness¹⁹ in treating the symptoms of AD, as discussed in the Introduction. Thus, isatoic anhydride **12** was reacted with the amino acids **13** and **14** to give the known benzodiazepinediones **15**³¹ and **16**³² which were brominated regioselectively to give the previously reported intermediates **17**³³ and **18**.³⁴ Condensation of **17** and **18** with ethyl isocyanoacetate **20** in the presence of chlorophosphate **19** proceeded without incident to furnish the known imidazobenzodiazepines **21**^{33,35} and **22**.³⁵ The bromobenzodiazepines **17**, **18**, **21** and **22** were then subjected to Sonogashira couplings with the (trialkylsilyl)acetylenes **23** and **24**, yielding the (trialkylsilyl)ethynyl-substituted benzodiazepines **25** – **31**. TBAF mediated deprotection produced the desired ethynyl-substituted benzodiazepines **32** – **35**. Compounds **26** – **30** and **35** are previously unreported, whereas compounds **25**,³⁶ **31**,¹⁸ **32**,³⁷ **33**^{19,36} and **34**¹⁸ have been reported. We chose to work with the known imidazo-fused systems **33** and **34** as reaction partners for the reasons described above. Compounds **32** and **35** were synthesized due to their ease of access from bromo-precursors **17** and **18**, and to provide useful comparators for later biological testing. It is also of note that, as far as we are aware, the alkynyl pyrrolobenzodiazepine **35** together with its precursor trialkylsilyl alkynes **29** and **30** have not been reported before. Similarly, trialkylsilyl alkynes **27** and **28** are not known in the literature, although the alkyne **32** has been reported in the patent literature, where it was accessed via an alkyne substituted derivative of isatoic anhydride **12**.³⁷

With the requisite alkynes **32** – **35** and azides **10** and **11** in hand, eight new 1,2,3-triazoles **36** – **43** were produced by reaction in the presence of a Cu(II)/ascorbate system, as shown in Scheme 3 and Table 1. The copper catalyzed azide-alkyne cycloadditions did not occur after reaction for two days at room temperature, showed no reaction after 24 hours at 50 °C, and showed only a small amount of product after 24 hours at 80 °C. It was found that 100 °C overnight (16 hours) was required for complete reactions to occur. No reaction was observed in the absence of copper, with toluene at reflux either returning the starting materials or, on prolonged heating, causing loss of the azide starting material by degradation.

The new triazole compounds were produced in sufficient purity (>95% by ¹H NMR) and amounts (10s of milligrams were produced, but only μLs of a 10 mM solution were used) for our biological testing requirements, which are described below. However, whilst all of the products were sufficiently soluble in DMSO to allow biological testing, the acetylated triazoles **40** – **43** were not sufficiently soluble to allow ¹³C NMR spectra to be recorded, and only just soluble enough to allow ¹H NMR data collection (see the Experimental Section and Supplementary Material). Nonetheless, for compounds **40** – **43**, the ¹H NMR data showed that the Cu(II)/ascorbate mediated cycloaddition reaction had clearly succeeded, a conclusion that was supported by the infra-red and HRMS data. All other compounds were fully characterized.



Scheme 2. Synthesis of Benzodiazepine Derivatives. *Reagents and conditions:* (a) **13** or **14**, DMSO, 120 °C, 4 h; (b) Br₂, NaOAc, AcOH, RT, 16 h; (c) 1. TEA, CH₃CN, 70 °C; 2. [Pd(PPh₃)₂Cl₂], **23** or **24**, 85 °C, 20 h; (d) TBAF, THF, RT, 15 min; (e) 1. *t*-BuOK, THF, 0 °C, 20 min; 2. **19**, -35 °C; 3. 0 °C, 30 min; 4. **20**, *t*-BuOK, -35 °C; 5. RT, 4 h.

**Scheme 3.** Synthesis of Novel 1,4-Disubstituted 1,2,3-Triazoles.**Table 1.** Synthesis of Novel 1,4-Disubstituted 1,2,3-Triazoles.

Alkyne	Isoflavone	Isoflavone/1,2,3-triazole/benzodiazepine hybrid (yield)
 35	10 11	 36, $\text{R}^1 = \text{H}$ (63% from 10); 40 , $\text{R}^1 = \text{CH}_3\text{CO}$ (91% from 11)
 32	10 11	 37, $\text{R}^1 = \text{H}$ (64% from 10); 41 , $\text{R}^1 = \text{CH}_3\text{CO}$ (84% from 11)
 34	10 11	 38, $\text{R}^1 = \text{H}$ (60% from 10); 42 , $\text{R}^1 = \text{CH}_3\text{CO}$ (82% from 11)
 33	10 11	 39, $\text{R}^1 = \text{H}$ (56% from 10); 43 , $\text{R}^1 = \text{CH}_3\text{CO}$ (71% from 11)

The 1,2,3-triazoles **36** – **43**, together with some key precursors and the original natural products **1** and **2**, were evaluated *in vitro* on LPS-stimulated BV2 mouse brain microglial cells as a preliminary screen for potential anti-inflammatory compounds, and the results are summarized in Table 2. Cell viability was performed using XTT assay³⁸ in order to determine if the compounds were toxic to the BV2 cells. BV2 mouse brain microglial cells are commonly used in place of primary microglia,³⁹ and have a key role in neuroinflammation.⁴⁰ When microglia are activated, for example, with LPS (lipopolysaccharide), pro-inflammatory mediators such as nitric oxide are produced.⁴¹ Activated microglia have been found next to amyloid β plaques in Alzheimer's disease,⁴² and are a recognized target for reducing inflammation and neurodegeneration. Nitric oxide production was measured using the Griess Assay.⁴³ NO is produced in small amounts by normal cells (Table 2 – entries 1 and 2: 20% NO production), but when the cells are LPS-activated, NO production increases significantly (Table 2, entry 3: 100% NO production). Table 2 shows that two of the novel hybrids (**39** and **43**), both derived from the imidazobenzodiazepine **33**, showed reasonable cell viability (> 60%) and significant inhibition of NO production (< 20%), when compared to the known anti-inflammatory natural products daidzein **1** and formononetin **2**, and so were selected for further pharmacological evaluation. The alkynyl benzodiazepines **32** – **35** were not cytotoxic but did not inhibit LPS-induced NO production when compared to daidzein **1** and formononetin **2**. The previously unreported azide **10** also showed good inhibition of NO production when compared to daidzein **1** and formononetin **2**, and so was selected for further study. We will report the results and full details of these ongoing pharmacological studies elsewhere, as it is beyond the remit of this journal.

Table 2. *In vitro* cell viability and NO production for Triazoles **36** – **43** and Selected Precursors

Compound No	Cell viability $\pm$ SEM (%) ^a	NO production $\pm$ SEM (%) ^b	MW
- ^c	107.46 $\pm$ 3.04	20.89 $\pm$ 0.79	
- DMSO	100.00 $\pm$ 0.00	20.08 $\pm$ 0.71	
+ ^d	83.52 $\pm$ 1.73	100.00 $\pm$ 0.00	
Daidzein, 1 ^e	106.63 $\pm$ 2.18	34.79 $\pm$ 2.43	254.24
Formononetin, 2	84.83 $\pm$ 5.59	72.70 $\pm$ 4.64	268.26
10	63.07 $\pm$ 4.15	29.09 $\pm$ 1.95	279.25
11	52.87 $\pm$ 7.80	31.40 $\pm$ 4.26	321.29
32	100.21 $\pm$ 3.89	95.73 $\pm$ 10.00	214.22
33	87.03 $\pm$ 2.30	82.87 $\pm$ 8.90	309.32
34	115.97 $\pm$ 1.73	90.06 $\pm$ 8.49	335.36
35	89.26 $\pm$ 4.64	96.70 $\pm$ 9.22	240.26
36	39.34 $\pm$ 8.65	29.45 $\pm$ 2.75	519.51
37	67.74 $\pm$ 5.13	51.6 $\pm$ 23.67	493.47
38	42.85 $\pm$ 6.51	18.06 $\pm$ 1.00	614.61
39	66.35 $\pm$ 9.97	19.99 $\pm$ 1.07	588.57
40	97.73 $\pm$ 13.76	64.28 $\pm$ 1.02	561.54
41	45.68 $\pm$ 3.20	18.15 $\pm$ 0.96	535.51
42	44.62 $\pm$ 7.50	17.76 $\pm$ 0.94	656.64
43	60.24 $\pm$ 5.79	19.88 $\pm$ 1.23	630.61

^a For cell viability, the % values are reported relative to negative control cells DMSO (- DMSO, 100%) that contained the amount of DMSO used to add the compound solutions in the cell medium. ^b For NO production, the % values are

reported relative to LPS-stimulated BV2 cells (+, 100%). ^c Negative control, - : BV2 cells were incubated for 24 h only with serum free medium RPMI. ^d LPS-stimulated cells, + : BV2 cells were incubated for 24 h with 100 ng/mL LPS in the medium. ^e Compounds: BV2 cells were incubated with the compounds at a concentration of 20 μ M (final concentration in well) and stimulated with 100 ng/mL LPS. Values are expressed as mean $\pm$ SEM (%) of minimum three experiments; SEM is standard error of mean. MW: molecular weight.

Conclusions

A series of 8 novel 1,2,3-triazole linked benzodiazepine substituted isoflavones was produced in 56 – 91% yield using a copper catalyzed azide-alkyne cycloaddition reaction between two previously unreported azido-isoflavones and four alkynyl-1,4-benzodiazepines. The alkynes were produced in good to excellent overall yields using Sonogashira couplings. The cell viability and inhibition of NO production in LPS-stimulated BV2 cells were determined for the novel triazole products and their precursors, and the results were compared to the parent natural products daidzein and formononetin. Two of the new 1,2,3-triazole linked benzodiazepine substituted isoflavones, both derived from the same imidazobenzodiazepine, and one of the azido-isoflavones, showed useful levels of activity (inhibition of NO production in LPS-stimulated BV2 cells greater than daidzein and much greater than formononetin) and are candidates for further pharmacological evaluation, the results of which will appear elsewhere.

Experimental Section

General. Reagents and anhydrous solvents were purchased from Fischer Scientific, Acros Organics, Sigma-Aldrich, VWR, Manchester Organics, Fluorochem and Alfa-Aesar, and were used as supplied, unless otherwise indicated. Compounds **8**,^{29,30} **9**,^{29,30} **16**,⁴⁴ **18**,³⁴ **22**,³⁵ **31**,¹⁸ **34**,¹⁸ **15**,³¹ **17**,²³ **32**,³⁷ **21**,³⁵ **25**³⁶ and **33**³⁶ are known and were synthesized as described in the Supplementary Information using the relevant literature method. The compounds reported below are all previously unreported.

Reactions were magnetically stirred, heated on a paraffin oil bath, and monitored on Merck TLC silica gel 60 F₂₅₄ aluminium sheets. Visualization of spots was accomplished using a UV lamp (254 or 365 nm) and/or staining with potassium permanganate solution. Column chromatography was performed on silica gel (Aldrich, technical grade, pore size 60 Å, 40–63 μ m particle size) using the solvent mixtures indicated (volume to volume ratios). Unless otherwise indicated, reactions were conducted under an atmosphere of dry nitrogen.

Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Ascend 400 (400 MHz – ¹H, and 100 MHz – ¹³C), Bruker Fourier 300 (300 MHz – ¹H, and 75 MHz – ¹³C), Bruker Avance 500 (500 MHz – ¹H, and 125 MHz – ¹³C) or Bruker Avance 600 (600 MHz – ¹H, and 150 MHz – ¹³C) spectrometers using CDCl₃, (CD₃)₂SO, (CD₃)₂CO, CD₃OD or D₂O as solvent and as internal standard. The chemical shifts (δ) are expressed in parts per million (ppm). The multiplicities were reported as s = singlet, d = doublet, t = triplet, q = quartet, br = broad signal, combinations of aforementioned multiplicities, and m = multiplet. Mass spectral experiments were performed on Agilent 6210 TOF MS (Dual ESI source), Agilent 6530 Q-TOF MS (Jet Stream ESI source), Agilent 1290 HPLC + 6530 Q-TOF (Dual AJESI source +ve) or Agilent 7890A-5975C (EI-GCMS) and spectra were recorded in positive mode. FT-IR spectra were recorded on a Thermo Nicolet 380 FT-IR Spectrometer with Diamond ATR (neat sample). Melting points were recorded using a Stuart SMP10 melting point apparatus.

3-(4-Azidophenyl)-7-hydroxy-4H-chromen-4-one (10). To a suspension of aminoisoflavone **9** (2.96 mmol, 750 mg) in anhydrous acetonitrile (6 mL) at 0 °C, *t*-BuONO (4.44 mmol, 458 mg, 0.59 mL) and TMSN₃ (4.44 mmol, 512 mg, 0.62 mL) were added dropwise, and the resulting mixture was stirred at room temperature for 1.5 h. The solvent was removed by rotary evaporation to give a crude product that was washed with CH₂Cl₂ (20 mL) to give azide **10** (725 mg, 75%) as a white solid; mp 198 °C (decomp.); *R*_f = 0.4 (CH₂Cl₂/CH₃OH, 95:5).

¹H-NMR (400 MHz, d₆-DMSO): δ 10.84 (s, 1 H, OH), 8.41 (s, 1H), 7.96 (d, 8.8 Hz, 1 H), 7.61 (d, *J* 8.5 Hz, 2 H), 7.17 (d, *J* 8.5 Hz, 2 H), 6.93 (dd, *J* 2.2, 8.8 Hz, 1 H), 6.87 (d, *J* 2.2 Hz, 1 H). ¹³C-NMR (100 MHz, d₆-DMSO): δ = 174.8 (C=O), 163.2 (qC), 157.9 (qC), 154.3 (CH), 139.3 (qC), 130.9 (2 CH), 129.4 (qC), 127.8 (CH), 123.1 (qC), 119.3 (2 CH), 117.0 (qC), 115.8 (CH), 102.6 (CH). HRMS (Dual ESI): calc *m/z* for C₁₅H₉N₃O₃: 279.0644 [M], 280.0717 [M+H]⁺, 252.0661 [M-N₂]⁺; found: 279.0648 [M], 280.0720 [M+H]⁺, 252.0665 [M-N₂]⁺. FT-IR (cm⁻¹): ν = 3232, 3050, 2099, 1619, 1575, 1565, 1506, 1376, 1264, 1093, 829.

3-(4-Azidophenyl)-4-oxo-4H-chromen-7-yl acetate (11). To a solution of azide **10** (1.79 mmol, 500 mg) in pyridine (3.6 mL), acetic anhydride (17.9 mmol, 1.7 mL) was added dropwise, and the resulting mixture was stirred at RT for 4 h. Water (20 mL) was added and the mixture was extracted with CH₂Cl₂ (3 × 25 mL). The organic extracts were dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography (CH₂Cl₂/CH₃OH, 100:1) to give compound **11** (490 mg, 85%) as a white solid; mp 179-180 °C; *R_f* = 0.7 (CH₂Cl₂/CH₃OH, 100:1). ¹H-NMR (400 MHz, CDCl₃): δ = 8.32 (d, *J* 8.7 Hz, 1 H), 8.00 (s, 1 H), 7.56 (d, *J* 8.5 Hz, 2 H), 7.31 (d, *J* 2.1 Hz, 1 H), 7.18 (dd, *J* 2.1, 8.7 Hz, 1 H), 7.10 (d, *J* 8.5 Hz, 2 H), 2.36 (s, 3 H, Me). ¹³C-NMR (100 MHz, CDCl₃): δ = 175.6 (C=O), 168.7 (C=O), 156.7 (qC), 154.6 (qC), 153.1 (CH), 140.2 (qC), 130.4 (2 CH), 128.3 (qC), 127.9 (CH), 124.8 (qC), 122.3 (qC), 119.7 (CH), 119.2 (2 CH), 111.1 (CH), 21.3 (CH₃).

HRMS (Jet stream ESI): calc *m/z* for C₁₇H₁₁N₃O₄: 321.0750 [M], 344.0642 [M+Na]⁺; found: 321.0762 [M], 344.0643 [M+Na]⁺. FT-IR (cm⁻¹): ν = 3088, 3047, 2980, 2121, 1750, 1620, 1576, 1506, 1440, 1360, 1287, 1241, 1211, 1183, 1098.

7-((Trimethylsilyl)ethynyl)-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-*a*][1,4]diazepine-5,11(10H)-dione (29). To a degassed solution of 7-bromobenzodiazepine **18** (1.7 mmol, 502 mg, 1.0 equiv.) in Et₃N (25 mL) and CH₃CN (20 mL), at 70 °C, PdCl₂(PPh₃)₂ (0.17 mmol, 120 mg, 10 mol %) and (trimethylsilyl)acetylene **23** (3.4 mmol, 334 mg, 0.47 mL) were added. After stirring the resulting mixture for 20 h at 85 °C under N₂, the solution was concentrated by rotary evaporation. Saturated aqueous NaHCO₃ (50 mL) was added and the crude was extracted with CH₂Cl₂ (3 × 30 mL). The organic phase was dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography (CH₂Cl₂/CH₃OH, 100:1) to give silylalkyne **29** (467 mg, 88%) as a pale white solid; mp 223-224 °C; *R_f* = 0.37 (CH₂Cl₂/CH₃OH, 100:2).

¹H-NMR (400 MHz, CDCl₃): δ = 9.45 (bs, 1 H, NH), 8.07 (d, *J* 1.8 Hz, 1 H), 7.49 (dd, *J* 1.8, 8.3 Hz, 1 H), 7.00 (d, *J* 8.3 Hz, 1 H), 4.04 (app d, *J* 6.9 Hz, 1 H, NCH), 3.79 – 3.75 (m, 1 H, NCHH), 3.55 – 3.60 (m, 1 H, NCHH), 2.74 – 2.76 (m, 1 H, CHH), 2.05 – 2.00 (m, 3 H, CH₂ + CHH), 0.22 (s, 9 H, SiMe₃). ¹³C-NMR (100 MHz, CDCl₃): δ = 171.3 (qC, C=O), 164.7 (qC, C=O), 135.4 (CH), 135.3 (qC), 135.0 (CH), 126.9 (qC), 121.2 (CH), 120.1 (qC), 103.4 (qC), 95.5 (qC), 56.8 (CH), 47.5 (CH₂), 26.3 (CH₂), 23.5 (CH₂), 0.0 (3 CH₃). HRMS (Dual ESI): calc *m/z* for C₁₇H₂₀N₂O₂Si: 312.1294 [M], 313.1367 [M+H]⁺; found: 312.1292 [M], 313.1365 [M+H]⁺. FT-IR (cm⁻¹): ν = 3229, 3139, 2952, 2897, 2154, 1692, 1632, 1604, 1491, 1436, 1374, 1247, 967.

7-((Triethylsilyl)ethynyl)-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-*a*][1,4]diazepine-5,11(10H)-dione (30) Prepared as described for compound **29** using 7-bromobenzodiazepine **18** (0.68 mmol, 200 mg), Et₃N (15 mL), CH₃CN (12 mL), PdCl₂(PPh₃)₂ (34 μmol, 24 mg, 5 mol %) and (triethylsilyl)acetylene **24** (1.36 mmol, 190 mg, 0.27 mL); purified by flash chromatography (EtOAc/PE, 2:3) to give compound **30** (205 mg, 85%) as a pale brown oily solid; *R_f* = 0.24 (EtOAc/PE, 1:1) which was characterized by NMR and used immediately in the next step.

¹H-NMR (400 MHz, CDCl₃): δ = 8.14 (d, *J* 1.9 Hz, 1 H), 7.97 (s, 1 H, NH), 7.56 (dd, *J* 1.9, 8.3 Hz, 1 H), 6.92 (d, *J* 8.3 Hz, 1 H), 4.07 (d, *J* 6.6 Hz, 1 H, NCH), 3.87 – 3.81 (m, 1 H, NCHH), 3.67 – 3.60 (m, 1 H, NCHH), 2.80 – 2.78 (m, 1 H, CHH), 2.06 – 2.04 (m, 3 H, CHH + CH₂), 1.06 (t, *J* 7.9 Hz, 9 H, 3 × SiCH₂CH₃), 0.69 (q, *J* 7.9 Hz, 6 H, 3 × SiCH₂Me).

¹³C-NMR (100 MHz, CDCl₃): δ = 170.6 (qC, C=O), 164.5 (qC, C=O), 135.5 (CH), 135.1 (CH), 134.5 (qC), 127.1 (qC), 120.8 (CH), 120.6 (qC), 104.4 (qC), 93.3 (qC), 56.7 (CH), 47.4 (CH₂), 26.3 (CH₂), 23.4 (CH₂), 7.5 (3 CH₃), 4.3 (3 CH₂).

7-Ethynyl-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-*a*][1,4]diazepine-5,11(10*H*)-dione (35). General method: TBAF (1.4 equiv., 1.0 M in THF, 5% water) was added dropwise to a solution of the trialkylsilyl protected compound (1.0 equiv.) in THF and the mixture was stirred at RT for 10-15 min. Water (20 mL) was added to the reaction mixture and the crude was extracted with ethyl acetate (3 × 30 mL). The organic phase was washed with brine (25 mL), dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography to give the deprotected product. Compound **35** was prepared according to the general method using TBAF (1.68 mmol, 438 mg, 1.68 mL), trimethylsilyl protected compound **29** (1.2 mmol, 374 mg) and THF (10 mL). The crude product was purified by flash chromatography (CH₂Cl₂/acetone, 9:1) to give compound **35** (273 mg, 95%) as a white solid; mp 236-237 °C; *R_f* = 0.2 (CH₂Cl₂/acetone, 9:1). Compound **35** was also prepared according to the general method using TBAF (0.81 mmol, 212 mg, 0.81 mL), triethylsilyl protected compound **30** (0.58 mmol, 205 mg) and THF (7 mL) to give compound **35** (125 mg, 90%). ¹H-NMR (400 MHz, CDCl₃): δ = 8.91 (s, 1 H, NH), 8.15 (d, *J* 1.9 Hz, 1 H), 7.58 (dd, *J* 1.9, 8.3 Hz, 1 H), 7.01 (d, *J* 8.3 Hz, 1 H), 4.07 (d, *J* 7.3 Hz, 1 H, NCH), 3.88 – 3.74 (m, 1 H, NCHH), 3.66 – 3.55 (m, 1 H, NCHH), 3.10 (s, 1 H, C≡CH), 2.84 – 2.70 (m, 1 H, CHH), 2.13 – 1.95 (m, 3 H, CHH + CH₂). ¹³C-NMR (100 MHz, CDCl₃): δ = 171.1 (qC), 164.5 (qC), 135.7 (CH), 135.4 (qC), 135.2 (CH), 127.1 (qC), 121.3 (CH), 119.2 (qC), 82.1 (qC, C≡CH), 78.3 (CH, C≡CH), 56.8 (CH), 47.5 (CH₂), 26.4 (CH₂), 23.5 (CH₂). HRMS (Dual ESI): calc *m/z* for C₁₄H₁₂N₂O₂: 240.0899 [M], 241.0972 [M+H]⁺; found: 240.0899 [M], 241.0971 [M+H]⁺. FT-IR (cm⁻¹): ν = 3232, 3159, 3050, 2941, 1700, 1620, 1596, 1475, 1438, 1266.

4-Methyl-7-((trimethylsilyl)ethynyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (27). Prepared as described for compound **29** using compound **17** (1.7 mmol, 457 mg), Et₃N (25 mL), CH₃CN (20 mL), PdCl₂(PPh₃)₂ (0.17 mmol, 120 mg, 10 mol %) and alkyne **23** (3.4 mmol, 334 mg, 0.47 mL); purified by flash chromatography (CH₂Cl₂/MeOH, 100:1) to give silylalkyne **27** (452 mg, 92%) as a pale white solid; mp 216-218 °C; *R_f* = 0.24 (CH₂Cl₂/acetone, 100:5). ¹H-NMR (400 MHz, CDCl₃): δ = 8.94 (s, 1 H, NH), 8.06 (d, *J* 1.9 Hz, 1 H), 7.52 (dd, *J* 1.9, 8.3 Hz, 1 H), 6.95 (d, *J* 8.3 Hz, 1 H), 3.88 (s, 2 H, CH₂), 3.28 (s, 3 H, NMe), 0.24 (s, 9 H, SiMe₃). ¹³C-NMR (100 MHz, CDCl₃): δ = 169.9 (qC, C=O), 166.5 (qC, C=O), 135.7 (CH), 135.5 (CH), 135.3 (qC), 126.6 (qC), 120.7 (qC), 120.6 (CH), 103.2 (qC), 96.0 (qC), 52.5 (CH₂), 36.7 (CH₃), 0.0 (3 CH₃). HRMS (Dual ESI): calc *m/z* for C₁₅H₁₈N₂O₂Si: 286.1138 [M], 287.1210 [M+H]⁺; found: 286.1144 [M], 287.1217 [M+H]⁺. FT-IR (cm⁻¹): ν = 3219, 3166, 3035, 2953, 2898, 2156, 1708, 1627, 1607, 1496, 1409, 1360, 1247, 994.

4-Methyl-7-((triethylsilyl)ethynyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (28). Prepared as described for compound **29** using compound **17** (0.74 mmol, 200 mg), Et₃N (15 mL), CH₃CN (12 mL), PdCl₂(PPh₃)₂ (37 μmol, 26 mg, 5 mol %) and triethylsilylalkyne **24** (1.49 mmol, 209 mg, 0.29 mL); purified by flash chromatography (EtOAc/PE, 2:3) to give compound **28** (201 mg, 82%) as a white waxy solid; *R_f* = 0.15 (EtOAc/PE, 1:1), which was characterized by NMR and used immediately in the next step. ¹H-NMR (400 MHz, CDCl₃): δ = 8.65 (s, 1 H, NH), 8.09 (d, *J* 1.9 Hz, 1 H), 7.55 (dd, *J* 1.9, 8.3 Hz, 1 H), 6.95 (d, *J* 8.3 Hz, 1 H), 3.90 (s, 2 H, CH₂), 3.30 (s, 3 H, Me), 1.05 (t, *J* 7.9 Hz, 9 H, 3 × SiCH₂CH₃), 0.69 (q, *J* 7.9 Hz, 6 H, 3 × SiCH₂Me). ¹³C-NMR (100 MHz, CDCl₃): δ = 169.8 (qC, C=O), 166.4 (qC, C=O), 135.6 (CH), 135.5 (CH), 135.1 (qC), 126.5 (qC), 120.8 (qC), 120.5 (CH), 104.3 (qC), 93.4 (qC), 52.4 (CH₂), 36.6 (CH₃), 7.4 (3 CH₃), 4.3 (3 CH₂).

Ethyl 5-methyl-6-oxo-8-((triethylsilyl)ethynyl)-5,6-dihydro-4H-benzo[f]imidazo[1,5-*a*][1,4]diazepine-3-carboxylate (26). Prepared as described for compound **29** using bromo-compound **21** (0.41 mmol, 150 mg), Et₃N (10 mL), CH₃CN (8 mL), PdCl₂(PPh₃)₂ (29 mg, 41 μmol, 10 mol %) and alkyne **24** (0.82 mmol, 116 mg, 0.15 mL); purified by flash chromatography (CH₂Cl₂/acetone, 100:4) to give compound **26** (167 mg, 96%) as a pale brown oil; *R_f* = 0.3 (CH₂Cl₂/acetone, 100:8), which was characterized by NMR and used immediately in the next step (see supplementary information). ¹H-NMR (400 MHz, CDCl₃): δ = 8.18 (d, *J* 1.8 Hz, 1 H), 7.93 (s, 1 H), 7.70 (dd, *J* 1.8, 8.3 Hz, 1 H), 7.39 (d, *J* 8.3 Hz, 1 H), 5.22 (bm, 1 H, OCHH), 4.55 – 4.28 (m, 3 H, OCHH + NCH₂), 3.26 (s, 3 H, NMe), 1.46 (t, *J* 7.1 Hz, 3 H, OCH₂CH₃), 1.06 (t, *J* 7.9 Hz, 9 H, 3 × SiCH₂CH₃), 0.70 (q, *J* 7.9 Hz, 6 H, 3 × SiCH₂Me).

^{13}C -NMR (100 MHz, CDCl_3): δ = 165.8 (qC), 162.8 (qC), 136.3 (CH), 135.6 (CH), 135.4 (qC), 134.8 (CH), 131.2 (qC), 129.1 (qC), 128.7 (qC), 124.3 (qC), 121.8 (CH), 103.5 (qC), 95.5 (qC), 61.1 (CH_2), 42.3 (CH_2), 35.9 (CH_3), 14.3 (CH_3), 7.4 (3 CH_3), 4.2 (3 CH_2).

General procedure for azide to alkyne cycloadditions. To a suspension of 4'-azidoisoflavone (1.0 equiv.) and the corresponding alkyne (1.0 equiv.) in a $\text{H}_2\text{O}/t\text{-BuOH}$ mixture (2:1 ratio), sodium ascorbate (0.1-0.2 equiv.) was added, followed by $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.02-0.05 equiv.). After the resulting mixture was stirred rapidly overnight at 100 °C, the end of reaction was confirmed by TLC and the mixture was diluted with 10 mL of water and cooled in ice. The precipitate was collected by filtration, washed with cold water (10 mL), CH_2Cl_2 (10 mL), and CH_3OH (10 mL) and dried under vacuum suction to give the desired hybrid.

7-(1-(4-(7-Hydroxy-4-oxo-4H-chromen-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione (36). Prepared according to the general procedure using azido compound **10** (107 μmol , 30 mg), alkyne **35** (107 μmol , 26 mg), $\text{H}_2\text{O}/t\text{-BuOH}$ (2:1 ratio, 3 mL), sodium ascorbate (21.5 μmol , 4.5 mg, 0.2 equiv.) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5.5 μmol , 1.5 mg, 0.05 equiv.); workup gave the product **36** (35 mg, 63%) as a pale brown solid; mp >300 °C; R_f = 0.4 ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$, 95:5). ^1H -NMR (400 MHz, d_6 -DMSO, d_6 -acetone): δ = 10.87 (s, 1 H, OH), 10.62 (s, 1 H, NH), 9.43 (s, 1 H), 8.54 (s, 1 H), 8.36 (d, J 2.0 Hz, 1 H), 8.07 (dd, J 2.0, 8.4 Hz, 1 H), 8.02 (d, J 8.6 Hz, 2 H), 8.00 (d, J 8.7 Hz, 1 H), 7.84 (d, J 8.6 Hz, 2 H), 7.24 (d, J 8.4 Hz, 1 H), 6.96 (dd, J 2.1, 8.7 Hz, 1 H), 6.90 (d, J 2.1 Hz, 1 H), 4.20 (d, J 7.9 Hz, 1 H, NCH), 3.66 – 3.58 (m, 1 H, NCHH), 3.52 – 3.44 (m, 1 H, NCHH), 2.01 – 1.76 (m, 4 H, $2 \times \text{CH}_2$). ^{13}C -NMR (100 MHz, d_6 -DMSO, d_6 -acetone): δ = 174.7 (qC), 171.0 (qC), 164.7 (qC), 163.2 (qC), 157.9 (qC), 154.8 (CH), 146.8 (qC), 136.6 (qC), 136.3 (qC), 133.0 (qC), 130.7 (2 CH), 129.2 (CH), 127.8 (CH), 127.6 (CH), 127.5 (qC), 126.4 (qC), 122.8 (qC), 122.5 (CH), 120.0 (3 CH), 117.0 (qC), 115.9 (CH), 102.7 (CH), 56.7 (CH), 47.4 (CH_2), 26.2 (CH_2), 23.5 (CH_2). HRMS (Dual ESI): calc m/z for $\text{C}_{29}\text{H}_{21}\text{N}_5\text{O}_5$: 519.1543 [M], 520.1615 [M+H] $^+$; found: 519.1542 [M], 520.1617 [M+H] $^+$. FT-IR (cm^{-1}): ν = 3204, 3140, 3085, 2980, 2881, 1693, 1620, 1604, 1567, 1441, 1378, 1259, 1040.

7-(1-(4-(7-Hydroxy-4-oxo-4H-chromen-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (37). Prepared according to the general procedure using azido compound **10** (107 μmol , 30 mg), alkyne **32** (107 μmol , 23 mg), $\text{H}_2\text{O}/t\text{-BuOH}$ (2:1 ratio, 3 mL), sodium ascorbate (21.5 μmol , 4.5 mg, 0.2 equiv.) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5.5 μmol , 1.5 mg, 0.05 equiv.); workup gave product **37** (34 mg, 64%) as a brown solid; mp >300 °C; R_f = 0.4 ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$, 95:5). ^1H -NMR (400 MHz, d_6 -DMSO, d_6 -acetone): δ = 10.88 (s, 1 H, OH), 10.59 (s, 1 H, NH), 9.43 (s, 1 H), 8.55 (s, 1 H), 8.32 (s, 1 H), 8.08 – 7.99 (m, 4 H), 7.84 (d, J 8.3 Hz, 2 H), 7.22 (d, J 8.4 Hz, 1 H), 6.96 (app d, J 8.9 Hz, 1 H), 6.91 (app s, 1 H), 3.91 (s, 2 H, CH_2), 3.15 (s, 3 H, Me). ^{13}C -NMR (100 MHz, d_6 -DMSO, d_6 -acetone): δ = 174.7 (qC), 170.1 (qC), 166.7 (qC), 163.2 (qC), 157.9 (qC), 154.8 (CH), 146.8 (qC), 137.2 (qC), 136.3 (qC), 133.0 (qC), 130.7 (2 CH), 129.1 (CH), 128.2 (CH), 127.8 (CH), 127.1 (qC), 126.4 (qC), 122.8 (qC), 121.9 (CH), 120.0 (3 CH), 117.0 (qC), 115.8 (CH), 102.7 (CH), 52.7 (CH_2), 36.4 (CH_3). HRMS (Dual ESI): calc m/z for $\text{C}_{27}\text{H}_{19}\text{N}_5\text{O}_5$: 493.1386 [M], 494.1459 [M+H] $^+$; found: 493.1389 [M], 494.1460 [M+H] $^+$. T-IR (cm^{-1}): ν = 3190, 3108, 3080, 2935, 1704, 1621, 1581, 1486, 1372, 1260, 1034.

Ethyl 7-(1-(4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate (38). Prepared according to the general procedure using azido compound **10** (107 μmol , 30 mg), alkyne **34** (107 μmol , 36 mg), $\text{H}_2\text{O}/t\text{-BuOH}$ (2:1 ratio, 3 mL), sodium ascorbate (21.5 μmol , 4.5 mg, 0.2 equiv.) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5.5 μmol , 1.5 mg, 0.05 equiv.); workup gave product **38** (40 mg, 60%) as a brown solid; mp 277 °C (decomp.); R_f = 0.4 ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$, 95:5). ^1H -NMR (400 MHz, d_6 -DMSO): δ = 10.90 (br s, 1 H, OH), 9.62 (s, 1 H), 8.57 (s, 1 H), 8.53 (s, 1 H), 8.32 (s, 1 H), 8.30 (d, J 8.6 Hz, 1 H), 8.06 (d, J 7.8 Hz, 2 H), 8.02 (d, J 7.9 Hz, 1 H), 7.91 – 7.82 (m, 3 H), 6.99 (d, J 8.4 Hz, 1 H), 6.93 (s, 1 H), 5.1 – 4.9 (bm, 1 H, NCH), 4.4 – 4.2 (bm, 2 H, NCH_2), 3.65 – 3.64 (m, 1 H, CHH), 3.50 – 3.48 (m, 1 H, CHH), 3.21 – 3.17 (m, 1 H, CHH), 2.23 – 2.09 (m, 3 H, CHH + CH_2), 1.44 – 1.24 (m, 3 H, Me). ^{13}C -NMR (100 MHz, d_6 -DMSO): δ = 174.6 (qC), 163.3 (qC), 163.2 (qC), 157.9 (qC), 155.9 (qC), 154.8 (CH), 146.1 (qC), 139.7 (qC), 136.2 (qC), 133.1 (qC), 130.7 (2 CH), 130.5 (qC), 130.0 (qC), 129.4 (CH), 127.8 (2 CH), 125.4 (CH), 122.7 (qC), 122.0 (qC), 120.9 (CH), 120.0 (3 CH), 117.0 (qC), 115.8 (CH), 102.6 (CH), 61.0 (CH_2), 46.7 (CH_2), 28.2 (CH_2),

24.4 (CH₂), 14.6 (CH₃). HRMS (Dual ESI): calc *m/z* for C₃₄H₂₆N₆O₆: 614.1914 [M], 615.1987 [M+H]⁺; found: 614.1908 [M], 615.1978 [M+H]⁺. FT-IR (cm⁻¹): ν = 3201, 3126, 3077, 2978, 2897, 1714, 1625, 1610, 1574, 1451, 1370, 1261, 1190, 1037.

Ethyl 8-(1-(4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (39). Prepared according to the general procedure using azido compound **10** (107 μ mol, 30 mg), alkyne **33** (107 μ mol, 31 mg), H₂O/*t*-BuOH (2:1 ratio, 3 mL), sodium ascorbate (21.5 μ mol, 4.5 mg, 0.2 equiv.) and CuSO₄·5H₂O (5.5 μ mol, 1.5 mg, 0.05 equiv.); workup gave alkyne **39** (33 mg, 56%) as a pale brown solid; mp 277 °C (decomp.); *R*_f = 0.4 (CH₂Cl₂/CH₃OH, 95:5).

¹H-NMR (400 MHz, d₆-DMSO, d₆-acetone): δ = 10.88 (br s, 1 H, OH), 9.58 (s, 1 H), 8.55 (s, 1 H), 8.47 (s, 1 H), 8.27 (d, *J* 8.0 Hz, 2 H), 8.09 – 7.97 (m, 3 H), 7.93 – 7.81 (m, 3 H), 7.03 – 6.86 (m, 2 H), 5.1 – 4.9 (bm, 1 H, CHH), 4.7 – 4.5 (bm, 1 H, CHH), 4.40 – 4.20 (m, 2 H, CH₂), 3.13 (s, 3 H, Me), 1.42 – 1.30 (m, 3 H, Me).

¹³C-NMR (100 MHz, d₆-DMSO, d₆-acetone): δ = 174.7 (qC), 165.9 (qC), 163.3 (qC), 158.0 (qC), 155.9 (qC), 154.9 (CH), 147.1 (qC), 146.1 (qC), 139.7 (qC), 136.2 (qC), 133.1 (qC), 130.7 (2 CH), 130.4 (qC), 129.8 (qC), 129.4 (CH), 128.7 (CH), 127.8 (CH), 124.2 (CH), 122.7 (qC), 122.0 (qC), 120.9 (CH), 120.0 (3 CH), 117.0 (qC), 115.9 (CH), 102.7 (CH), 60.6 (CH₂), 35.6 (CH₃), 14.7 (CH₃). HRMS (Dual ESI): calc *m/z* for C₃₂H₂₄N₆O₆: 588.1757 [M], 589.1830 [M+H]⁺; found: 588.1752 [M], 589.1824 [M+H]⁺. FT-IR (cm⁻¹): ν = 3321, 3210, 3115, 3078, 2980, 1702, 1624, 1573, 1500, 1457, 1377, 1258, 1194, 1035.

3-(4-(4-(5,11-Dioxo-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-7-yl)-1H-1,2,3-triazol-1-yl)phenyl)-4-oxo-4H-chromen-7-yl acetate (40). Prepared according to the general procedure using azido compound **11** (93 μ mol, 30 mg), alkyne **35** (93 μ mol, 23 mg), H₂O/*t*-BuOH (2:1 ratio, 3 mL), sodium ascorbate (18.7 μ mol, 4 mg, 0.2 equiv.) and CuSO₄·5H₂O (4.7 μ mol, 1.5 mg, 0.05 equiv.); workup gave product **40** (48 mg, 91%) as a pale brown solid; mp >300 °C. ¹³C-NMR data could not be collected due to poor solubility.

¹H-NMR (400 MHz, d₆-DMSO): δ = 10.65 (s, 1 H), 9.47 (s, 1 H), 8.72 (s, 1 H), 8.38 (d, *J* 2.1 Hz, 1 H), 8.22 (d, *J* 8.7 Hz, 1 H), 8.13 – 8.05 (m, 3 H), 7.89 (d, *J* 8.6 Hz, 2 H), 7.64 (d, *J* 2.1 Hz, 1 H), 7.36 (dd, *J* 2.1, 8.7 Hz, 1 H), 7.27 (d, *J* 8.5 Hz, 1 H), 4.23 (d, *J* 7.9 Hz, 1 H, NCH), 3.70 – 3.60 (m, 1 H, NCHH), 3.55 – 3.45 (m, 1 H, NCHH), 2.36 (s, 3 H, Me), 2.05 – 1.75 (m, 4 H, 2 × CH₂). HRMS (Dual ESI): calc *m/z* for C₃₁H₂₃N₅O₆: 561.1648 [M], 562.1721 [M+H]⁺; found: 561.1652 [M], 562.1724 [M+H]⁺. FT-IR (cm⁻¹): ν = 3213, 3149, 3078, 2980, 2884, 1750, 1682, 1615, 1567, 1520, 1484, 1434, 1371, 1208, 1181, 1098, 1034.

3-(4-(4-(4-Methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-7-yl)-1H-1,2,3-triazol-1-yl)phenyl)-4-oxo-4H-chromen-7-yl acetate (41). Prepared according to the general procedure using azido compound **11** (93 μ mol, 30 mg), alkyne **32** (93 μ mol, 20 mg), H₂O/*t*-BuOH (2:1 ratio, 3 mL), sodium ascorbate (18.7 μ mol, 4 mg, 0.2 equiv.) and CuSO₄·5H₂O (4.7 μ mol, 1.5 mg, 0.05 equiv.); workup gave compound **41** (42 mg, 84%) as a pale brown solid; mp >300 °C. ¹³C-NMR data could not be collected due to poor solubility. ¹H-NMR (400 MHz, d₆-DMSO): δ = 10.59 (s, 1 H), 9.44 (s, 1 H), 8.70 (s, 1 H), 8.32 (app s, 1 H), 8.20 (d, *J* 8.6 Hz, 1 H), 8.11 – 8.00 (m, 3 H), 7.87 (d, *J* 8.2 Hz, 2 H), 7.61 (app s, 1 H), 7.34 (app d, *J* 8.9 Hz, 1 H), 7.22 (app d, *J* 8.3 Hz, 1 H), 3.91 (s, 2 H, CH₂), 3.15 (s, 3 H, Me), 2.33 (s, 3 H, Me). HRMS (Dual ESI): calc *m/z* for C₂₉H₂₁N₅O₆: 535.1492 [M], 536.1565 [M+H]⁺; found: 535.1507 [M], 536.1577 [M+H]⁺. FT-IR (cm⁻¹): ν = 3232, 3148, 3077, 2980, 2875, 1748, 1695, 1633, 1574, 1486, 1435, 1362, 1222, 1183, 1033.

Ethyl 7-(1-(4-(7-Acetoxy-4-oxo-4H-chromen-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate (42). Prepared according to the general procedure using azido compound **11** (93 μ mol, 30 mg), alkyne **34** (93 μ mol, 31 mg), H₂O/*t*-BuOH (2:1 ratio, 3 mL), sodium ascorbate (18.7 μ mol, 4 mg, 0.2 equiv.) and CuSO₄·5H₂O (4.7 μ mol, 1.5 mg, 0.05 equiv.); workup gave compound **42** (50 mg, 82%) as a brown solid; mp 262 °C (decomp.). ¹³C-NMR data could not be collected due to poor solubility. ¹H-NMR (400 MHz, d₆-DMSO): δ = 9.63 (s, 1 H), 8.72 (s, 1 H), 8.52 (d, *J* 1.9 Hz, 1 H), 8.30 (br s, 1 H), 8.29 (dd, *J* 1.9, 8.0 Hz, 1 H), 8.21 (d, *J* 8.7 Hz, 1 H), 8.08 (d, *J* 8.6 Hz, 2 H), 7.90 – 7.85 (m, 3 H), 7.63 (d, *J* 2.1 Hz, 1 H), 7.35 (dd, *J* 2.1, 8.7 Hz, 1 H), 4.97 (d, *J* 8.0 Hz, 1 H, NCH), 4.29 (q, *J* 7.0 Hz, 2 H, CH₂Me), 3.66 – 3.62 (m, 1 H, NCHH), 3.48 – 3.44 (m, 1 H, NCHH), 3.22 – 3.16 (m, 1 H, CHH), 2.34 (s, 3 H, Me), 2.21 – 2.07 (m, 3 H, CHH + CH₂), 1.30 (t, *J* 7.0 Hz, 3 H, Me). HRMS (Dual ESI): calc *m/z* for C₃₆H₂₈N₆O₇: 656.2019

[M], 657.2092 [M+H]⁺; found: 656.2008 [M], 657.2081 [M+H]⁺. FT-IR (cm⁻¹): ν = 3078, 2980, 2890, 1770, 1713, 1639, 1610, 1557, 1519, 1437, 1366, 1181, 1103, 1036.

Ethyl 8-(1-(4-(7-acetoxy-4-oxo-4H-chromen-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (43). Prepared according to the general procedure using azido compound **11** (93 μ mol, 30 mg), alkyne **33** (93 μ mol, 29 mg), H₂O/*t*-BuOH (2:1 ratio, 3 mL), sodium ascorbate (18.7 μ mol, 4 mg, 0.2 equiv.) and CuSO₄·5H₂O (4.7 μ mol, 1.5 mg, 0.05 equiv.), overnight at 100 °C; workup gave compound **43** (42 mg, 71%) as a brown solid; mp 274 °C (decomp.). ¹³C-NMR data could not be collected due to poor solubility.

¹H-NMR (400 MHz, d₆-DMSO): δ = 9.60 (s, 1 H), 8.71 (s, 1 H), 8.48 (app d, *J* 1.2 Hz, 2 H), 8.28 (app dd, *J* 1.2, 8.0 Hz, 1 H), 8.21 (d, *J* 8.4 Hz, 1 H), 8.06 (d, *J* 8.6 Hz, 2 H), 7.95 – 7.85 (m, 3 H), 7.62 (d, *J* 2.0 Hz, 1 H), 7.35 (dd, *J* 2.0, 8.4 Hz, 1 H), 5.1 – 4.9 (bm, 1 H, CHH), 4.7 – 4.5 (bm, 1 H, CHH), 4.41 – 4.23 (m, 2 H, CH₂), 3.14 (s, 3 H, NMe), 2.34 (s, 3 H, Me), 1.39 – 1.28 (m, 3 H, Me). HRMS (Dual ESI): calc *m/z* for C₃₄H₂₆N₆O₇: 630.1863 [M], 631.1936 [M+H]⁺; found: 630.1870 [M], 631.1943 [M+H]⁺. FT-IR (cm⁻¹): ν = 3115, 3062, 2981, 1752, 1731, 1661, 1638, 1602, 1573, 1495, 1438, 1372, 1212, 1157, 1037.

Acknowledgements

We thank the University of Huddersfield for a PhD studentship (to GM), Dr Neil McLay (NMR), Dr Jack Blackburn and Dr Sean Ward (HRMS) for analytical support.

Supplementary Material

Methods and characterization data for the synthesis of known compounds **8**, **9**, **16**, **18**, **22**, **31**, **34**, **15**, **17**, **32**, **21**, **25** and **33**, full details of the biological methodology, and copies of NMR spectra for previously unreported compounds can be found in the Supplementary Material. This material can be accessed using the link "Supplementary Material" in the journal issue contents page.

References

1. Al-Maharik, N. *Nat. Prod. Rep.* **2019**, *36*, 1156.
<http://doi.org/10.1039/c8np00069g>
2. Křížová, L.; Dadáková, K.; Kašparovská, J.; Kašparovský, T. *Molecules* **2019**, *24*, 1076.
<http://doi.org/10.3390/molecules24061076>
3. Yu, J.; Bi, X.; Yu, B.; Chen, D. *Nutrients*, **2016**, *8*, 361.
<http://doi.org/10.3390/nu8060361>
4. Occhiuto, F.; Palumbo, D. R.; Samperi, S.; Zangla, G.; Pino, A.; De Pasquale, R.; Circosta, C. *Phytother. Res.* **2009**, *23*, 192.
<http://doi.org/10.1002/ptr.2584>
5. Xiao, H.; Qin, X.; Wan, J.; Li, R. *Med. Sci. Monit.* **2019**, *25*, 4273.
<http://doi.org/10.12659/MSM.916662>
6. Wei, J.; Yang, F.; Gong, C.; Shi, X.; Wang, G. *J. Biochem. Mol. Toxicol.* **2019**, *33*, e22319.
<http://doi.org/10.1002/jbt.22319>

7. Ko, Y.-H.; Kim, S. Y.; Lee, S.-Y.; Jang, C.-G. *Eur. J. Pharmacol.* **2018**, 826, 140.
<http://doi.org/10.1016/j.ejphar.2018.02.048>
8. Van Eldik, L. J.; Carrillo, M. C.; Cole, P. E.; Feuerbach, D.; Greenberg, B. D.; Hendrix, J. A.; Kennedy, M.; Kozauer, N.; Margolin, R. A.; Molinuevo, J. L.; Mueller, R.; Ransohoff, R. M.; Wilcock, D. M.; Bain, L.; Bales, K. *Alzheimers Dement.* **2016**, 2, 99.
<http://doi.org/10.1016/j.trci.2016.05.001>
9. Prasad, N. K. *Mechanisms of Aging and Development* **2017**, 162, 63.
<http://doi.org/10.1016/j.mad.2016.12.003>
10. Wang, D.; Hu, M.; Li, X.; Zhang, D.; Chen, C.; Fu, J.; Shao, S.; Shi, G.; Zhou, Y.; Wu, S.; Zhang, T. *Eur. J. Med. Chem.* **2019**, 168, 207.
<http://doi.org/10.1016/j.ejmech.2019.02.053>
11. Stefanini, C.; Colivicchi, M. A.; Della Corte, L.; Ward, R. J.; De Witte, P.; Lallemand, F.; Hemming, K.; Pitard, A.; Page M. I.; Nayak, K.; Dexter, D. T. *J. Alcohol. Drug Depend.* **2014**, 2, 150.
<http://doi.org/10.4172/2329-6488.1000150>
12. Velagapudi, R.; Jamshaid, F.; Lepiarz, I.; Katola, F. O.; Hemming, K.; Olajide, O. A. *Int. Immunopharmacol.* **2019**, 77, 105951.
<http://doi.org/10.1016/j.intimp.2019.105951>
13. Hemming, K.; Chambers, C. S.; Jamshaid, F.; O'Gorman, P. A. *Molecules* **2014**, 19, 16737.
<http://doi.org/10.3390/molecules191016737>
14. Abbot, V.; Sharma, P.; Dhiman, S.; Noolvi, M. N.; Patel, H. M.; Bhardwaj, V. *RSC Adv.*, **2017**, 7, 28313.
<http://doi.org/10.1039/c6ra24662a>
15. Desmidt, T.; Delrieu, J.; Lebouvier, T.; Robert, G.; David, R.; Balageas, A.-C.; Surget, A.; Belzung, C.; Arlicot, N.; Ribeiro, M.-J.; Payoux, P.; Vellas, B.; El-Hage, W.; Tavernier, E.; Camus, V. *Neurobiology of Aging* **2019**, 84, 61.
<http://doi.org/10.1016/j.neurobiolaging.2019.08.008>
16. Revot, T. D.; Li, G.; Cook, J. M.; Sibille, E. *ACS Chem. Neurosci.* **2019**, 10, 2088.
<http://doi.org/10.1021/acschemneuro.9b00148>
17. Li, G.; Stephen, M. R.; Kodali, R.; Zahn, N. M.; Poe, M. M.; Tiruveedhula, V. V. N. P. B.; Huber, A. T.; Schussman, M. K.; Qualmann, K.; Panhans, C. M.; Raddatz, N. J.; Baker, D. A.; Prevot, T. D.; Banasr, M.; Sibille, E.; Arnold, L. A.; Cook, J. M. *Arkivoc* **2018**, iv, 158.
<http://doi.org/10.24820/ark.5550190.p010.460>
18. Li, X.; Yu, J.; Atack, J. R.; Cook, J. M. *Med. Chem. Res.* **2004**, 13, 259.
<http://doi.org/10.1007/s00044-004-0033-7>
19. Xu, N. Z.; Ernst, M.; Treven, M.; Cerne, R.; Wakulchik, M.; Li, X.; Jones, T. M.; Gleason, S. D.; Morrow, D.; Schkeryantz, J. M.; Rahman, M. T.; Li, G.; Poe, M. M.; Cook, J. M.; Witkin, J. M., *Psychopharmacology* **2018**, 235, 1151.
<http://doi.org/10.1007/s00213-018-4832-9>
20. Huang, Q.; He, X.; Ma, C.; Liu, R.; Yu, S.; Dayer, C. A.; Wenger, G. R.; McKernan, R.; Cook, J. M. *J. Med. Chem.* **2000**, 43, 71.
<http://doi.org/10.1021/jm990341r>
21. Hamasharif, M. S.; Smith, O. E. P.; Curran, C. J.; Hemming, K. *ACS Omega*, **2017**, 2, 1222.
<http://doi.org/10.1021/acsomega.7b00211>
22. Bozorov, K.; Zhao, J.; Aisa, H. A. *Bioorg. Med. Chem.* **2019**, 27, 3511.
<http://doi.org/10.1016/j.bmc.2019.07.005>

23. Dorababu, A. *Bioorg. Chem.* **2019**, *93*, 103299.
<http://doi.org/10.1016/j.bioorg.2019.103299>
24. Yerrabelly, J. R.; Mallepaka, P.; *Russ. J. Gen. Chem.* **2020**, *90*, 911.
<http://doi.org/10.1134/S1070363220050266>
25. Gregson, S. J.; Masterson, L. A.; Wei, B.; Pillow, T. H.; Spencer, S. D.; Kang, G.-D.; Yu, S.-F.; Raab, H.; Lau, J.; Li, G.; Lewis Phillips, G. D.; Gunzner-Toste, J.; Safina, B. S.; Ohri, R.; Darwish, M.; Kozak, K. R.; de la Cruz-Chuh, J.; Polson, A.; Flygare, J. A.; Howard, P. W. *J. Med. Chem.* **2017**, *60*, 9490.
<http://doi.org/10.1021/acs.jmedchem.7b00736>
26. Kamal, A.; Prabhakar, S.; Ramaiah, M. J.; Reddy, P. V.; Reddy, Ch. R.; Mullareddy, A.; Shankaraiah, N.; Reddy, T. L. N.; Pushpavalli, S. N. C. V. L.; Pal-Bhadra, M. *Eur. J. Med. Chem.* **2011**, *46*, 3820.
<http://doi.org/10.1016/j.ejmech.2011.05.050>
27. Kamal, A.; Ramu, R.; Khanna, G. B. R.; Saxena, A. K.; Shanmugavel, M.; Pandita, R. M. *Arkivoc* **2005**, *iii*, 83.
<http://doi.org/10.3998/ark.5550190.0006.311>
28. Mehrazar, M.; Hassankalhor, M.; Toolabi, M.; Goli, F.; Moghimi, S.; Nadri, H.; Bukhari, S. N. A.; Firoozpour, L.; Foroumadi, A. *Molecular Diversity* **2019**. In press, published on-line.
<http://doi.org/10.1007/s11030-019-10008-x>
29. Gao, G.-Y.; Li, D.-J.; Keung, W. M. *Bioorg. Med. Chem.* **2003**, *11*, 4069.
[https://doi.org/10.1016/S0968-0896\(03\)00397-3](https://doi.org/10.1016/S0968-0896(03)00397-3)
30. Wang, W.; He, Y.; Xu, P.; You, Q.; Xia, H.; Xiang, H.; *Bioorg. Med. Chem.* **2015**, *23*, 4428.
<http://doi.org/10.1016/j.bmc.2015.06.032>
31. Kim, D. H. *J. Heterocycl. Chem.*, **1975**, *12*, 1323.
<http://doi.org/10.1002/jhet.5570120647>
32. Pettersson, B.; Hasimbegovic, V.; Bergman, J. *J. Org. Chem.*, **2011**, *76*, 1554.
<http://doi.org/10.1021/jo101864n>
33. Preshlock, S.; Calderwood, S.; Verhoog, S.; Tredwell, M.; Huiban, M.; Hienzs, A.; Gruber, S.; Wilson, T. C.; Taylor, N. J.; Cailly, T.; Schedler, M.; Collier, T. L.; Passchier, J.; Smits, R.; Mollitor, J.; Hoepping, A.; Mueller, M.; Genicot, C.; Mercier, J.; Gouverneur, V. *Chem. Commun.*, **2016**, *52*, 8361.
<http://doi.org/10.1039/c6cc03295h>
34. Lindner, A. S.; Geist, E.; Gjikaj, M.; Schmidt, A. *J. Heterocycl. Chem.*, **2014**, *51*, 423.
<http://doi.org/10.1002/jhet.1775>
35. Yang, J.; Teng, Y.; Ara, S.; Rallapalli, S.; Cook, J. M. *Synthesis*, **2009**, 1036.
<http://doi.org/10.1055/s-0028-1083358>
36. Liu, R.; Hu, R. J.; Zhang, P.; Skolnick, P.; Cook, J. M. *J. Med. Chem.*, **1996**, *39*, 1928.
<https://doi.org/10.1021/jm950887n>
37. Cook, J. M.; Clayton, T.; Johnson, Y. T.; Rallapalli, S.; Han, D. US Patent, **2009**, US20100130479A1.
38. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. *Cancer Res.*, **1988**, *48*, 4827.
<http://cancerres.aacrjournals.org/content/48/17/4827>
39. Henn, A.; Lund, S.; Hedtj rn, M.; Schrattenholz, A.; P rzig, P.; Leist, M. *ALTEX*, **2009**, *26*, 83.
<http://doi.org/10.14573/altex.2009.2.83>
40. Parakalan, R.; Jiang, B.; Nimmi, B.; Janani, M.; Jayapal, M.; Lu, J.; Tay, S. S. W.; Ling, E.-A.; Dheen, S. T. *BMC Neurosci.*, **2012**, *13*, 64.
<http://doi.org/10.1186/1471-2202-13-64>
41. Bol s, M.; Perea Juan, R.; Avila, J. *Biomol. Concepts*, **2017**, *8*, 37.

<http://doi.org/1515/bmc-2016-0029>

42. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S. T.; Hampel, H. ; Hull, M.; Landreth, G.; Lue, L. F.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk G.; Wyss–Coray, T. *Neurobiol. Aging*, **2000**, *21*, 383.

[http://doi.org/10.1016/S0197-4580\(00\)00124-X](http://doi.org/10.1016/S0197-4580(00)00124-X)

43. Sun, J.; Zhang, X.; Broderick, M.; Fein, H. *Sensors*, **2003**, *3*, 276.

<https://doi.org/10.3390/s30800276>

44. Wright Jr., W. B.; Brabander, H. J.; Greenblatt, E. N.; Day, I. P.; Hardy Jr., R. A. *J. Med. Chem.* **1978**, *21*, 1087.

DOI: <http://doi.org/10.1021/jm00208a017>

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)